(NASDAQ:CRAI). Fuller & Thaler Asset Inc has invested 0.01% in CRA International, Inc. (NASDAQ:SCMP) or 15 shares. The firm owned 20,213 shares of the biopharmaceutical company's stock after selling 1,299 shares during the period. Leerink Swann also issued estimates for Sucampo Pharmaceuticals' FY2019 earnings at $1.79 EPS, FY2020 earnings at $2.02 EPS and FY2021 earnings at $2.19 EPS. Trexquant Investment LP bought a new stake in Sucampo Pharmaceuticals in the third quarter valued at about $122,000. When we look at the Volatility of the company, Week Volatility is at 3.25% whereas Month Volatility is at 2.78%.
Sucampo Pharmaceuticals, Inc.is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. The stock decreased 0.14% or $0.02 during the last trading session, reaching $18.38. Finally, Nine Chapters Capital Management LLC purchased a new stake in shares of Sucampo Pharmaceuticals in the third quarter valued at $127,000. Insiders own 4.13% of the company's stock. Its 52-week high and low range is between $18.75 and $9.3. (NASDAQ:SCMP) shares have certain options and should contact the Shareholders Foundation.
More notable recent Sucampo Pharmaceuticals, Inc.
The average investment recommendation on a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell) is 2.70 for SCMP and 2.80 for IONS, which implies that analysts are more bullish on the outlook for IONS. Finally, assumed coverage on Sucampo Pharmaceuticals in a report on Wednesday, November 15th.
Sucampo Pharmaceuticals, Inc. (SCMP) surprised the stock market in its last reported earnings when it earned $0.27 a piece versus the consensus-estimated $0.25. Sucampo Pharmaceuticals had a net margin of 6.29% and a return on equity of 44.19%. The low EPS estimate is $0.25, while the high EPS estimate is $0.36. The company's quarterly revenue was up 73.4% on a year-over-year basis.
Several other equities research analysts have also recently weighed in on SCMP. They issued a "buy" rating and a $43.00 price target on the stock. According to today's trading volume Sucampo Pharmaceuticals, Inc.is ABOVE its 20-Day Avg. volume with the stock showing ABOVE Abnormal volume in the past 150 days.
Among 13 analysts covering Sucampo Pharma (NASDAQ:SCMP), 5 have Buy rating, 0 Sell and 8 Hold. The stock has an average rating of Buy and a consensus target price of $21.58. Kiener Peter A had sold 50,000 shares worth $825,000 on Thursday, December 7. The shares were sold at an average price of $15.58, for a total transaction of $27,514.28. Prudential Financial Inc. now owns 410,323 shares of the biopharmaceutical company's stock worth $4,842,000 after purchasing an additional 368,090 shares during the last quarter. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. This metric reflects the average amount a stock's price has differed from the mean over a period of time. Arrowstreet Capital Ltd Partnership invested in 66,363 shares or 0.01% of the stock. The disclosure for this sale can be found here. (NASDAQ:SCMP). Smith Asset Mngmt Grp L P owns 6,680 shares for 0% of their portfolio.
2017, Sucampo Pharmaceuticals, Inc. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom. (NASDAQ:SCMP) on Thursday, August 6 with "Hold" rating. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.